Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asiaticoside for Treating Overweight/Obesity
NCT07241533Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of asiaticoside in obesity, sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Change in Metabolic Rate at 4 weeks and Change in Body Weight at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
asiaticoside
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07241533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241533.